GeneDx received a raised fair value assessment and a cautious analyst rating for its stock.
2 reports, 2 independent
Updated Jul 31
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GeneDx received a raised fair value assessment and a cautious analyst rating for its stock.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.GeneDx stock received a raised fair value assessment and cautious analyst rating.1 source
GeneDx revenue growth exceeded industry average.1 source
Keep exploring
The entities involved
-
GeneDx
company in Stamford, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- Motley FoolWhy GeneDx Holdings Stock Crushed It Again Today Several pundits raised their price targets on the specialty healthcare company. This was hardly a surprise, as they came on the heels of an excellent
- Simply Wall St.GeneDx Holdings Second Quarter 2025 Earnings: Beats Expectations Revenue: US$102.7m (up 46% from 2Q 2024). Net income: US$10.8m (up from US$29.2m loss in 2Q 2024). Profit margin: 11% (up from net los